Date: 2017-01-18
Type of information: Services contract
Compound: manufacturing platform for allogeneic cell therapies
Company: Servier (France) MaSTherCell (Belgium)
Therapeutic area: Technology - Services
Type agreement: services contract manufacturing
Action mechanism: cell therapy
Disease:
Details: * On January 18, 2017, Servier and MaSTherCell SA, the full-service contract development and manufacturing organization (CDMO) specializing in the delivery of optimized process industrialization capacities to cell therapy organizations, announced the signing of a master service agreement for the development of a manufacturing platform for allogeneic cell therapies. Under the master service agreement, MaSTherCell is developing a CAR-T cell therapy manufacturing platform, which will enable industrial and commercial manufacturing of Servier cell therapy products. One of the most advanced cell therapies is based on CAR-T technology, where the T-cells are armed with a Chimeric Antigen Receptor. Servier is developing UCART-19, with two clinical trials currently ongoing in Europe, in relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL), in pediatric and adults patients. MaSTherCell anticipates that it will complete the development of the initial CAR-T platform in 2018. This will then be an efficient complement to the bioproduction facilities that Servier is developing at its site at Gidy (France), which will mainly focus on the production of antibodies.
Financial terms:
Latest news:
